Polysomy is associated with poor outcome in 1p/19q codeleted oligodendroglial tumors.
Adolescent
Adult
Aged
Aged, 80 and over
Aneuploidy
Brain Neoplasms
/ genetics
Chemotherapy, Adjuvant
Child
Chromosomal Instability
Chromosome Deletion
Chromosomes, Human, Pair 1
/ genetics
Chromosomes, Human, Pair 19
/ genetics
Female
Humans
In Situ Hybridization, Fluorescence
Isocitrate Dehydrogenase
/ genetics
Male
Middle Aged
Neoadjuvant Therapy
Neurosurgical Procedures
Oligodendroglioma
/ genetics
Prognosis
Progression-Free Survival
Radiotherapy, Adjuvant
Survival Rate
Young Adult
1p/19q codeletion
glioma
oligodendroglioma
polysomy
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
06 09 2019
06 09 2019
Historique:
pubmed:
30
5
2019
medline:
11
11
2020
entrez:
30
5
2019
Statut:
ppublish
Résumé
Chromosomal instability is associated with earlier progression in isocitrate dehydrogenase (IDH)-mutated astrocytomas. Here we evaluated the prognostic significance of polysomy in gliomas tested for 1p/19q status. We analyzed 412 histologic oligodendroglial tumors with use of 1p/19q testing at 8 institutions from 1996 to 2013; fluorescence in situ hybridization (FISH) for 1p/19q was performed. Polysomy was defined as more than two 1q and 19p signals in cells. Tumors were divided into groups on the basis of their 1p/19q status and polysomy and were compared for progression-free survival (PFS) and overall survival (OS). In our cohort, 333 tumors (81%) had 1p/19q loss; of these, 195 (59%) had concurrent polysomy and 138 (41%) lacked polysomy, 79 (19%) had 1p/19q maintenance; of these, 30 (38%) had concurrent polysomy and 49 (62%) lacked polysomy. In agreement with prior studies, the group with 1p/19q loss had significantly better PFS and OS than did the group with 1p/19q maintenance (P < 0.0001 each). Patients with 1p/19q loss and polysomy showed significantly shorter PFS survival than patients with 1p/19q codeletion only (P < 0.0001), but longer PFS and OS than patients with 1p/19q maintenance (P < 0.01 and P < 0.0001). There was no difference in survival between tumors with >30% polysomic cells and those with <30% polysomic cells. Polysomy had no prognostic significance on PFS or OS in patients with 1p/19q maintenance. The presence of polysomy in oligodendroglial tumors with codeletion of 1p/19q predicts early recurrence and short survival in patients with 1p/19q codeleted tumors.
Sections du résumé
BACKGROUND
Chromosomal instability is associated with earlier progression in isocitrate dehydrogenase (IDH)-mutated astrocytomas. Here we evaluated the prognostic significance of polysomy in gliomas tested for 1p/19q status.
METHODS
We analyzed 412 histologic oligodendroglial tumors with use of 1p/19q testing at 8 institutions from 1996 to 2013; fluorescence in situ hybridization (FISH) for 1p/19q was performed. Polysomy was defined as more than two 1q and 19p signals in cells. Tumors were divided into groups on the basis of their 1p/19q status and polysomy and were compared for progression-free survival (PFS) and overall survival (OS).
RESULTS
In our cohort, 333 tumors (81%) had 1p/19q loss; of these, 195 (59%) had concurrent polysomy and 138 (41%) lacked polysomy, 79 (19%) had 1p/19q maintenance; of these, 30 (38%) had concurrent polysomy and 49 (62%) lacked polysomy. In agreement with prior studies, the group with 1p/19q loss had significantly better PFS and OS than did the group with 1p/19q maintenance (P < 0.0001 each). Patients with 1p/19q loss and polysomy showed significantly shorter PFS survival than patients with 1p/19q codeletion only (P < 0.0001), but longer PFS and OS than patients with 1p/19q maintenance (P < 0.01 and P < 0.0001). There was no difference in survival between tumors with >30% polysomic cells and those with <30% polysomic cells. Polysomy had no prognostic significance on PFS or OS in patients with 1p/19q maintenance.
CONCLUSIONS
The presence of polysomy in oligodendroglial tumors with codeletion of 1p/19q predicts early recurrence and short survival in patients with 1p/19q codeleted tumors.
Identifiants
pubmed: 31140557
pii: 5505367
doi: 10.1093/neuonc/noz098
pmc: PMC7571489
doi:
Substances chimiques
IDH2 protein, human
EC 1.1.1.41
Isocitrate Dehydrogenase
EC 1.1.1.41
IDH1 protein, human
EC 1.1.1.42.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1164-1174Subventions
Organisme : NINDS NIH HHS
ID : R01 NS102669
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS102665
Pays : United States
Organisme : NINDS NIH HHS
ID : R03 NS087349
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA221747
Pays : United States
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
J Neuropathol Exp Neurol. 2018 Jul 1;77(7):542-548
pubmed: 29741737
J Clin Oncol. 2006 Jun 20;24(18):2707-14
pubmed: 16782910
J Neurooncol. 2017 May;133(1):183-192
pubmed: 28421459
Arch Neurol. 1999 Apr;56(4):434-6
pubmed: 10199331
Cancer Genet Cytogenet. 2008 Jul 15;184(2):77-86
pubmed: 18617055
J Exp Clin Cancer Res. 1999 Sep;18(3):305-9
pubmed: 10606174
N Engl J Med. 2015 Jun 25;372(26):2499-508
pubmed: 26061753
Science. 2011 Sep 9;333(6048):1453-5
pubmed: 21817013
Clin Cancer Res. 2009 Oct 15;15(20):6430-7
pubmed: 19808867
J Neuropathol Exp Neurol. 2012 Jul;71(7):618-24
pubmed: 22710961
Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6021-6
pubmed: 23530248
Acta Neuropathol. 2004 Jul;108(1):49-56
pubmed: 15118874
J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9
pubmed: 9776413
Front Biosci. 2003 Jan 01;8:a1-9
pubmed: 12456321
J Neurooncol. 2004 Nov;70(2):161-81
pubmed: 15674476
Neuro Oncol. 2013 Sep;15(9):1244-50
pubmed: 23861470
Acta Neuropathol. 2018 Jul;136(1):153-166
pubmed: 29687258
J Neuropathol Exp Neurol. 2004 Apr;63(4):314-22
pubmed: 15099021
J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26
pubmed: 12578221
J Neuropathol Exp Neurol. 2006 Oct;65(10):988-94
pubmed: 17021403
N Engl J Med. 2015 Jun 25;372(26):2481-98
pubmed: 26061751
Cancer Res. 2006 Oct 15;66(20):9852-61
pubmed: 17047046
Cancer. 1995 Nov 15;76(10):1809-13
pubmed: 8625052